Botanical species · safety record

Dysphania botrys

The EFSA Compendium of Botanicals holds 21 constituent measurements and 4 adverse-effect records for Dysphania botrys. This page reports what those source records contain and how to reach them. It carries no effect estimate, no dose and no recommendation.

Accepted name in source: Dysphania botrys (L.) Mosyakin & Clemants

21Constituent measurements
4Safety records
8Cited sources
0Licensed products (Canada)

Also recorded as

Synonyms are carried from the source compendium. A species may be traded and studied under more than one name, which is exactly how a safety record gets lost.

Regulatory presence

No Health Canada licensed natural health product in the snapshot names this species as a medicinal ingredient under this exact binomial. Absence here means absence from this one register under this one name, not absence from trade, and not a safety verdict.

What the records describe

Constituents measured

  • (+)-pulegone3
  • Alpha-thujone2
  • Ascaridol2
  • Camphor2
  • Fenchone2
  • Isoascaridole2
  • Myrcene2
  • Alkaloids1
  • Carvone1
  • Guaianolides1

Plant parts

  • Aerial part of plants10
  • Unspecified4
  • Leaves3
  • Fruit unspecified1

Preparations

  • Essential oil14
  • Solvent extraction7
  • Fresh4

Effect types

  • Digestive4

Target tissues

  • Digestive4

Recorded constituents

What analytical work has found in this species, at which plant part and preparation. A measured constituent is a fact about material, not about effect.

SubstancePlant partPreparationConcentrationAnalytical methodSource
SaponinsAerial part of plantsSolvent extractionResolve DOI
TanninsAerial part of plantsSolvent extractionResolve DOI
(+)-pulegoneAerial part of plantsEssential oil1 PercentGC-MSNo resolvable identifier
(+)-pulegoneUnspecifiedFresh3.7 PercentGaschromatography (GC)No resolvable identifier
(+)-pulegoneEssential oilStandard Chromatographic tests (paper- thin layer- and column chromatography)No resolvable identifier
AlkaloidsFruit unspecifiedSolvent extractionNo resolvable identifier
Alpha-thujoneUnspecifiedFresh2.9 PercentGaschromatography (GC)No resolvable identifier
Alpha-thujoneEssential oilStandard Chromatographic tests (paper- thin layer- and column chromatography)No resolvable identifier
AscaridolLeavesEssential oil4.2 PercentGC-MSNo resolvable identifier
AscaridolEssential oilStandard Chromatographic tests (paper- thin layer- and column chromatography)No resolvable identifier
CamphorEssential oilStandard Chromatographic tests (paper- thin layer- and column chromatography)No resolvable identifier
CamphorUnspecifiedFresh4.3 PercentGaschromatography (GC)No resolvable identifier
CarvoneAerial part of plantsEssential oil6.3 PercentGC-MSNo resolvable identifier
FenchoneEssential oilStandard Chromatographic tests (paper- thin layer- and column chromatography)No resolvable identifier
FenchoneUnspecifiedFresh2.8 PercentGaschromatography (GC)No resolvable identifier
GuaianolidesEssential oilGC-MSNo resolvable identifier
IsoascaridoleAerial part of plantsEssential oil7 PercentGC-MSNo resolvable identifier
IsoascaridoleLeavesEssential oil2.5 PercentGC-MSNo resolvable identifier
MenthoneEssential oilStandard Chromatographic tests (paper- thin layer- and column chromatography)No resolvable identifier
MyrceneLeavesEssential oil1.9 PercentGC-MSNo resolvable identifier
MyrceneAerial part of plantsEssential oil1.8 PercentGC-MSNo resolvable identifier

Recorded adverse effects

Adverse effects reported in the source literature, most often in animal or laboratory models at a stated preparation and dose.

EffectTarget tissuePlant partPreparationTest organismTest typeSource
DigestiveDigestiveAerial part of plantsSolvent extractionIn vitroResolve DOI
DigestiveDigestiveAerial part of plantsSolvent extractionIn vitroResolve DOI
DigestiveDigestiveAerial part of plantsSolvent extractionIn vitroResolve DOI
DigestiveDigestiveAerial part of plantsSolvent extractionIn vitroResolve DOI

Cited sources

The literature the compendium cites for this species. Metatron Health has no relationship with these authors or journals and earns nothing from citing them.

  1. Rustembekova, G. B., Goryaev, M. I., Krotova, G. I., Dembitskii, A. D. Substances added to the composition of essential oils. 60. Oxygen-containing compounds of Chenopodium botrys essential oil.. Izvestiya Akademii Nauk Kazakhskoi SSR, Seriya Khimicheskaya, 1975, vol. 25, no. 5, p. 32-4.
  2. Buchbauer, Gerhard., Jirovetz, Leopold., Wasicky, Michael., Walter, Johannes., Nikiforov, Alexej. Headspace volatiles of Chenopodium botrys (Chenopodiaceae). Journal of Essential Oil Research, 1995, p. 305-308.
  3. Dembitsky, Valery., Shkrob, Ilya., Hanus, Lumir Ondrej. Ascaridole and related peroxides from the genus Chenopodium. Biomedical Papers, 2008, p. 209-215.
  4. Sadykov, Yu. D., Khodzhimatov, M., Komarov, Yu. I. Alkaloids of Chenopodium botrys L. fruit.. Rastitel'nye Resursy, 1978, vol. 14, no. 3, p. 385-7.
  5. Ozer, MS., Sarikurkcu, C., Tepe, B. Phenolic composition, antioxidant and enzyme inhibitory activities of ethanol and water extracts of Chenopodium botrys. RSC ADVANCES, 2016, vol. 6, no. 69, p. 64986-64992. DOI
  6. El-Sayed, Aly M. Sesquiterpene constituents of Chenopodium botrys and Venidium decurrens.. Zagazig Journal of Pharmaceutical Sciences, 1994, vol. 3, no. 3A, p. 131-5.
  7. Feizbakhsh, A., Sedaghat, S., Tehrani, MS., Rustaiyan, A., Masoudi, S. Chemical composition of the essential oils of Chenopodium botrys L. from two different locations in Iran. JOURNAL OF ESSENTIAL OIL RESEARCH, 2003, vol. 15, no. 3, p. 193-194.
  8. Morteza-Semnani, Katayoun., Babanezhad, Esmaeil. Essential oil composition of Chenopodium botrys L. from Iran. JOURNAL OF ESSENTIAL OIL BEARING PLANTS, 2007, vol. 10, no. 4, p. 314-317.

Boundary

A constituent measurement is a fact about material at a stated preparation, not a statement about what that material does in a person. An adverse-effect or genotoxicity record is an observation reported in a source, most often in an animal or laboratory model. Neither is a Metatron Health conclusion about causality, human risk or benefit, and the absence of a record is not proof that a preparation is safe. Nothing here is diagnosis, prescribing or individual medical care.

Continue